Scalable efficient expansion of mesenchymal stem cells in xeno free media using commercially available reagents

Neil H Riordan1*, Marialaura Madrigal1,2,3, Jason Reneau4, Kathya de Cupeiro1, Natalia Jiménez1, Sergio Ruiz1, Nelsy Sanchez1, Thomas E Ichim5, Francisco Silva6 and Amit N Patel6

Abstract

Background: The rapid clinical translation of mesenchymal stem cells (MSC) has resulted in the development of cell-based strategies for multiple indications. Unfortunately one major barrier to widespread implementation of MSC-based therapies is the limited supply of fetal calf serum (FCS) used to expand cells to therapeutic numbers. Additionally, the xenogeneic element of fetal calf serum has been previously demonstrated to stimulate antibody mediated reactions and in some cases sensitization leading to anaphylaxis.

Method: XcytePLUS™ media, a human platelet lysate based product, was used to supplement the culture medium at 5, 7.5 and 10% and compared to fetal calf serum at 10%, for human umbilical cord MSC expansion. Properties of the expanded cells were investigated.

Results: This study demonstrated equivalent or superior effects of human platelet lysate compared to standard FCS supplemented media, based on doubling rate, without loss of identity or function, as demonstrated with flow cytometry characterization. Differentiation into osteocytes, adipocytes and chondrocytes was comparable from cells expanded in either media supplement.

Conclusions: These data support the implementation of human platelet lysate supplemented media as an alternative to xenogeneic containing preparations which may lead to safer MSC products with therapeutic uses.

Background

Tissue culture originated with the work of Alexis Carrell at the beginning of the 20th century utilizing a variety of undefined media additives such as embryonic and muscle extracts mixed with saline plasma, which were able to maintain cardiac cells in vitro and allow for contractile function [1]. The introduction of fetal calf serum (FCS) as a media additive revolutionized the field of tissue culture and allowed for laboratories to maintain stable cell lines in vitro, which catalyzed major efforts in cancer research [2]. The concept of utilizing cells as therapeutics originated in the bone marrow transplant area, in which uncultured donor bone marrow stem cells were used for hematopoietic support to allow for high dose chemotherapy and radiation therapy [3]. The utilization of cellular immunotherapy, in the 1980s was the first major clinical experiments that required expansion of cells in vitro. In these early experiments, it was demonstrated that fetal calf serum posed some potential to induce adverse effects. For example, a study reported that syngeneic lymphocytes cultured in FCS and subsequently administered to HIV patients resulted in Arthus reaction and fever in recipients, which was associated with antibodies to FCS components [4]. Other studies have shown that both pre-existing natural, as well as inducible antibodies are present in patients that recognize various components of FCS [5–8]. Additionally, activation of both T cell and NK cell responses have been reported subsequent to stimulation with FCS [9, 10].

Mesenchymal stem cells (MSC) are fibroblast-shaped cells capable of multigenic differentiation into bone, fat and cartilage, as well as differentiation into neuronal,
hepatic and pancreatic tissue [11]. A number of clinical trials have been performed utilizing MSC in conditions ranging from hepatic failure [12], type 1 diabetes [13], and stroke [14]. The majority of these clinical trials have utilized MSCs that are grown in FCS containing media. Overall safety has been demonstrated of MSC, as reported in a meta-analysis of clinical trials involving over 1,000 patients [15]. Interestingly, in these trials administration doses were 1–3 injections, thus substantially decreasing the possibility of sensitization. Despite this, some evidence of sensitization has been reported. Specifically, Le Blanc et al. demonstrated in 12 patients being administered bone marrow MSC for treatment of steroid resistant graft versus host disease (GVHD) the development of antibodies to fetal calf serum proteins as detected by ex vivo treatment of fetal calf proteins [16].

In order to overcome limitations associated with FCS, numerous groups have developed serum-free tissue culture media compositions for growing and expansion of MSC. Platelet derived growth factor (PDGF) is a potent cellular mitogen and has been reported to be a significant component of FCS allowing for cellular proliferation in vitro [17]. Since platelet lysate contains significant concentrations of PDGF, as well as numerous other mitogenic factors [18], investigators have utilized this as a potential substitute for FCS. In 2006 Müller et al. reported that bone marrow MSC cultures can be initiated and maintained in media in which FCS was substituted with platelet lysate [19]. The MSC grown in platelet lysate substituted media retained both differentiation, as well as immune modulatory activity. Numerous other studies have demonstrated that various platelet lysate preparations are capable of maintaining or increasing proliferation of bone marrow MSC as a substitute for FCS [20–35]. Another report on 213 patients treated with autologous BM MSC cultured in platelet lysate reported no adverse reactions subsequent to intradisc and intrajoint administration [36]. Some characterization has occurred of active components of platelet lysate. Specifically, antibody blocking studies have shown that up to 75% inhibition of MSC proliferation in response to platelet lysate was achieved with a combination of anti-bFGF + anti-PDGF-BB and anti-TGF-β1 + anti-PDGF-BB. Interestingly, various combinations of recombinant PDGF-BB, bFGF and TGF-β1 were not sufficient to promote cell proliferation, implying some components still remain unknown [37].

Despite advancements that have been reported utilizing platelet lysate, several obstacles still remain for large-scale commercial application, namely: (a) establishing the role that platelet lysate plays in increasing anti-inflammatory activity of MSC when compared to culture in FCS [38, 39]; (b) significant variation in MSC cultures depending on platelet donor profiles [40], with age being a contributing factor [41]; and (c) institution-specific proprietary methods for large-scale commercial production of platelet lysate, and the roles of factors such as heparin [42], or fibrinogen [39], concentration post large-scale production. Addressing these points will allow for a better standardized method for large-scale commercial production.

Here we present data using a commercially available platelet-lysate based media, XcytePLUS™, to culture human umbilical cord’s Wharton’s Jelly MSC (WJ-MSC) in comparison to media containing FCS. Additionally, the culture system described is completely free of xenogeneic components in that dissociation media did not contain bovine trypsin. We report equivalent or superior proliferation, and differentiation activity of WJ-MSC cultured in XcytePLUS™ media as compared to FCS.

Methods

Cells and tissue culture

Wharton’s Jelly mesenchymal stem cells were isolated from healthy donors according to Secco et al. [43]. Briefly, umbilical cords of minimum 25 cm long were dissected, and cut in pieces of 8 cm, and they were digested using Collagenase 1.67% (Sigma C9891) during 60 min at 37°C. Tissue was washed twice and all supernatant centrifuged to collect the pellet and then plated at 1 × 10^4 cells/cm². Cells were cultured using MEM alpha (Life 32561102) supplemented with 2 mM GlutaMax (Life 35050-079) and 10% FCS (Life 16000044).

All Isolated MSCs were frozen in Passage 2. Immunophenotype characterization was performed and based on those results, four lots were selected from a stock of cells to continue the experiments.

MSCs were thawed and plated into 6 well plates (6 wells per treatment), 5 × 10^4 cells/well, using XcytePLUS™ (iBiologics XPGS-001-500) (5, 7.5, and 10%) or 10% FCS supplemented media in two different laboratories. Cells were grown up to 80–90% confluence, then passaged using Tryple Express (Life Technologies), splits were 1:6, up to passage 6. Cell counts were performed every passage before re-plating to determine cell-doubling time. Finally, cells were frozen for further analysis of membrane markers expression and differentiation.

Flow cytometry

Flow cytometry was performed using Guava EasyCyte Mini (Millipore) flow cytometer. Antibodies CD105, CD73, CD90, CD34, CD45 were purchased from (BD pharmingen), isotype controls for FITC and RPE were utilized.
Doubling rate
Doubling rate of the cells was assessed by counting the cells in every passage. Number of doublings was calculated by the equation:

\[ X = \frac{\log(n) - \log(n_0)}{\log(2)}, \]

\( n = \) number of cells obtained, \( n_0 = \) number of cells plated.

Statistical analysis
For the statistical analysis, comparison of averages were made using GraphPad (Prism 6) software. Two-way ANOVA with Tukey test was used for doublings per day, cumulative number of cells and characterization analysis. One-way ANOVA was used for inter-laboratory analysis. In all tests a confidence interval of 95% was used.

Differentiation assays
Two lots were used for the differentiation assay. Briefly, 24 well plates were used and differentiation medium was prepared using DMEM low glucose, without phenol red (Life Technologies) supplemented with 2 mM glutaMax and 10% FCS. Adipogenesis media was supplemented with 1 \( \mu \)M dexamethasone, 500 \( \mu \)M 3-isobutyl-1-methylxantine, 60 \( \mu \)M indometacine, 5 \( \mu \)g/ml insulin. Chondrogenesis media with 0.1 \( \mu \)M dexamethasone, 50 \( \mu \)M ascorbate-2-phosphate, 1 mM sodium pyruvate, 1% ITS Premix, 10 ng/ml TGF-\( \beta \)1, and Osteogenesis media with 0.1 \( \mu \)M dexamethasone, 50 \( \mu \)M ascorbate-2-phosphate, 10 mM \( \beta \)-glycerophosphate. After 21 days, alcian blue, alizarin red and oil red O were used to stain chondrocytes, osteocytes and adipocytes, respectively.

Results
Doubling rate superior with WJ-MSC cultured in XCyte Media versus FCS
WJ-MSC after 5 passages were plated in media containing 5, 7.5 and 10% XcytePLUS\textsuperscript{TM}, or 10% FCS supplemented media and cultured for 9 days. Morphological differences were not found between the treatment groups (Figure 1).

![Figure 1](image_url)  
Morphology of WJ-MSC is not altered by supplementation of culture media with XcytePLUS\textsuperscript{TM} compared to Fetal Calf Serum (FCS). 10X inverted phase contrast microscope images of WJ-MSC cultured in a 10% FCS, b 5% XcytePLUS\textsuperscript{TM}, c 7.5% XcytePLUS\textsuperscript{TM} and d 10% XcytePLUS\textsuperscript{TM} on passage 5.
Significantly higher number of WJ-MSC were collected on day 9 with the 10% XcytePLUS™ supplemented media (average $1.4 \times 10^7$) as compared to 10% FCS media (average $7.5 \times 10^6$) ($p < 0.05$). Average numbers are represented in Figure 2. Furthermore, population doublings in 9 days were 8.37 for cells supplemented with 10% XcytePLUS™ and 7.29 using 10% FCS. Doublings per day did not show statistical difference when different lots of XcytePLUS™ were used (Figure 3). Furthermore, doubling rate experiments performed on the same four lots in different laboratories did not show substantial differences (Figure 4).

**Maintenance of MSC phenotype**

In order to assess whether WJ-MSC were not altered by culturing in XcytePLUS™ media from a phenotypic perspective, flow cytometric analysis was performed at the completion of 9 days of culture. As seen in Figure 5, cells maintained the markers of CD105+, CD73+, CD90+ throughout the culture period, which was not affected significantly by the type of media utilized. CD34 and CD45 expression was maintained negative, consistent with classical MSC phenotype.

**Differentiation potential**

Cells at passage 6 grown under 5, 7.5 or 10% XcytePLUS™ Media or 10% FCS were exposed to adipogenic, osteogenic and chondrogenic differentiation conditions. As seen in Figure 6, differentiation ability of WJ-MSC was not affected by XcytePLUS™ or FCS supplementation.

**Discussion**

The current findings provide for the first time data on reproducibility of a commercially available xenogenic
free media supplement and cell dissociation technique assessed across WJ-MSC donors. Equivalent or superior induction of cell proliferation was noted, as well as retention of classical MSC surface markers for 6 passages. Reproducibility of results between two independent laboratories was demonstrated.

Currently there is substantial controversy in the area of platelet lysate based cultures with various investigators providing contradictory results. Furthermore the field is complicated by lack of widespread access to various proprietary reagents utilized in the manufacture of the platelet lysate. Specifically, conditions such as concentration of heparin, fibronectin or donor characteristics all contribute to variability of product. XcytePLUS™ media is commercially available and is based on stringent characterized donors with large lots, thereby decreasing lot to lot variability.

Even though it has been reported that platelet lysate substitution for FCS results in a lower ability to differentiate into both adipogenic and osteogenic lineages, our data does not support this finding [44]. Due to enhanced proliferation rates with platelet lysate media, population doublings could be higher compared to FCS supplemented media. We have demonstrated that population doublings should be controlled so that the cells can retain differentiation ability.

Conclusions
The large-scale production of clinical grade MSCs demands a xeno-free standardized culture system. Feasibility of the use of XcytePLUS™ was demonstrated with consistent results in proliferation rate, characterization and differentiation potential. XcytePLUS™ is a pooled human platelet lysate product, which allows for a commercial therapeutic MSC product.

Author's contributions
NHR and MM conceived and designed the experiment. NHR, MM, JR, KC, NJ, SR, NS, TEL, FS, ANP were involved in experimental design, execution of experiments, and writing of the manuscript. All authors read and approved the final manuscript.

Author details
1 Medistem Panama, Inc., Building 221, City of Knowledge, Clayton, Panama City, Republic of Panama. 2 Indicasat AIP Panama, City of Knowledge, Rep. of Panama. 3 Acharya Nagarjuna University, Guntur, India. 4 Amniotic Therapies, LLC, Farmers Branch, TX, USA. 5 Coma Research Institute, La Jolla, CA, USA. 6 University of Utah School of Medicine, Salt Lake City, UT, USA.

Figure 6 Differentiation potential is retained in culture with XcytePLUS™. WJ-MSC maintained for 6 passages in the indicated culture conditions. Expanded cells were subjected to adipocytic (a-d), osteogenic (e-h), and chondrogenic (i-l) differentiation conditions as described in “Methods”. Morphological observations indicated no differences in differentiation efficacy between the groups.
Acknowledgements
This work was funded by internal grants from the Department of Cardiothoracic Surgery at the University of Utah, Salt Lake City, Utah.

Compliance with ethical guidelines
The authors declare that they have no competing interests.

Received: 14 April 2015 Accepted: 3 June 2015
Published online: 17 July 2015

References

1. Carrel A (1912) On the permanent life of tissues outside of the organism. J Exp Med 15(5):516–528
2. Sheddl M, Rubin H, Gerhart J (1972) Neutralization of growth-inhibitory material present in calf serum by conditioning factors elaborated by chick embryo cells in culture. Exp Cell Res 74(2):375–382
3. Thomas ED (1983) Bone marrow transplantation: a lifesaving applied art. An interview with E. Donald Thomas, MD. JAMA 249(18):2528–2536
4. Selvaggi TA, Walker RE, Fleisher TA (1997) Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood 89(3):776–779
5. Irie RF, Irie K, Morton DL (1974) Natural antibody in human serum to a neoantigen in human cultured cells grown in fetal bovine serum. J Natl Cancer Inst 52(4):1051–1058
6. Macy E et al (1989) Anaphylaxis to infusion of autologous bone marrow: an apparent reaction to self, mediated by IgE antibody to bovine serum albumin. J Allergy Clin Immunol 83(5):871–875
7. Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A (2000) Presence of IgG antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother 49(3):152–156
8. Kadi N, Potron N, Ouyar M, Jegou D, Gouin E, Bach JM et al (2007) Fetal serum pulse-expanded dendritic cells induce a strong anti-fetal calf serum immune response and diabetes protection in the non-obese diabetic mouse. Immunol Lett 108(2):129–136
9. Forti G, Green I (1976) Heterologous sera: a target for in vitro cell-mediated cytotoxicity. J Immunol 116(6):1561–1565
10. Lauer SJ, Finlan J, Borella LD, Piaskowski VD, Casper JT (1983) In vitro enhancement of peripheral blood mononuclear cell natural killer activity following short term incubation with fetal calf serum. J Clin Lab Immunol 12(2):105–110
11. Arsen-Zakay H, Lazaropec P, Nagler A (2010) Tissue regeneration potential in human umbilical cord blood. Best Pract Res Clin Haematol 23(2):291–303
12. Obermaier N, Popp FC, Johnson CL, Benseler V, Dahlke MH (2014) Ration- ale and prospects of mesenchymal stem cell therapy for liver transplantation. Curr Opinion Organ Transplant 19(1):60–64
13. Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H et al (2013) Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocirine J 60(3):347–357
14. Hoo W, Liu X, Tan C, Han Y, Kang C, Quan W et al (2014) Stem cell transplantation for treating stroke: status, trends and development. Neural Regen Res 9(17):1643–1648. doi:10.4103/1673-5374.141783
15. Kaplan JM, Youd ME, Lodie TA (2011) Immunomodulatory activity of mesenchymal stem cells. Curr Stem Cell Res Ther 5(4):297–316
16. Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K et al (2007) No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 92(9):1208–1215
17. Bowen-Pope DF, Ross R (1986) Platelet-derived growth factor. Clin Endocrinol Metab 13(1):191–205
18. Eastment CT, Sirbasku DA (1980) Human platelet lysate contains growth factor activities for established cell lines derived from various tissues of several species. In Vitro 16(8):694–705
19. Muller I, Kordowich S, Holzwarth C, Spano C, Iesensee G, Stabler A et al (2006) Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 8(5):437–444. doi:10.1017/s1463240606020782
20. Lange C, Calioglu F, Speiss AN, Cappallo-Obermann H, Dierlamm J, Zander AR (2007) Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for tissue regeneration and regenerative medicine. J Cellular Physiol 213(1):18–26. doi:10.1002/jcp.21081
21. Schallmoser K, Bartmann C, Rohde E, Reinsich A, Kashafer K, Stadelmeyer E et al (2007) Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfus ion 47(8):1436–1446. doi:10.1111/j.1600-2289.2007.01220.x
22. Capelli C, Domenghini M, Borleri G, Bellavita P, Poma R, Carobbio A et al (2007) Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 40(8):785–791. doi:10.1038/sj.bmt.1707598
23. Carrancio S, Lopez-Holgado N, Sanchez-Guijo FM, Villaron E, Barbado V, Tabera S et al (2008) Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification. Experimental Hematol 36(8):1014–1021
24. Salvador A, Della Mina P, Caddi D, Gatto F, Villa A, Bigoni M et al (2010) Characterization of platelet lysate cultured mesenchymal stromal cells and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue Eng Part C 16(2):201–214. doi:10.1089/ten.TEC.2008.0572
25. Bieback K, Hecker A, Koczaer A, Lannert H, Schallmoser K, Strunk D et al (2009) Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 27(9):2331–2341
26. Crespo-Diaz R, Behfar A, Butler GW, Padley DJ, Sarr MG, Bartunek J et al (2011) Platelet lysate consisting of a natural repair promotes human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant 20(6):797–811
27. Xia W, Li H, Wang Z, Xu R, Fu Y, Zhang X et al (2011) Human platelet lysate supports ex vivo expansion and enhances osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Cell Biol Int 35(6):639–643
28. Kinzebach S, Bieback K (2013) Expansion of mesenchymal stem/stromal cells under xenogenic-free culture conditions. Adv Biochem Eng Biotech- nol 129:33–57
29. Wannke PH, Humpe A, Strunk D, Stephens S, Wannke F, Wittfang J et al (2013) A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies. J Curr Innovatol Surg 41(2):153–161
30. Fekete N, Rojevski MT, Furtst D, Kreja L, Ignatus A, Dausend J et al (2012) GMP-compliant isolation and large-scale expansion of bone marrow- derived MSC. PloS One 7(8):e43255
31. Bernardi M, Albiero E, Alighis A, Chiaregato K, Lieveore C, Madoe D et al (2013) Production of human platelet lysate by use of ultrasound for ex vivo expansion of human bone marrow-derived mesenchymal stem cells. Cytotherapy 15(8):920–929
32. Mojica-Henshaw MP, Jacobson P, Morris J, Kelley L, Pierce J, Boyer M et al (2013) Serum-converted platelet lysate can substitute for fetal bovine serum in human mesenchymal stem cell cultures. Cytotherapy 15(12):1458–1468
33. Shanskii YD, Sergeeva NS, Sviridova IK, Kirakozov MS, Kirsanova VA, Akhemedova SA et al (2013) Human platelet lysate as a promising growth-stimulating additive for culturing of stem cells and other cell types. Bull Exp Biol Med 156(1):164–151
34. Lidicone P, Fioravanti D, Bonanno G, Miceli M, Lavorino C, Totta P et al (2014) Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells. J Transl Med 12:28
35. Shih DT, Burnouf T (2014) Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion. Int J Biotechnol 8(4):e43255
36. Centeno CJ, Schultz JR, Cheever M, Robinson B, Freeman M, Marasco W (2010) Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther 5(1):81–93
37. Fekete N, Gadelorge M, Furst D, Maurer C, Dausend J, Fleury-Cappelless S et al (2012) Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 14(5):540–554
38. Abdelrazik H, Spaggiari GM, Chiossone L, Moettta L (2011) Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur J Immunol 41(11):3281–3290
39. Copland IB, Garcia MA, Waller EK, Roback JD, Galipeau J (2013) The effect of platelet lysate fibrinogen on the functionality of MSCs in immunotherapy. Biomaterials 34(32):7840–7850
40. Horn P, Bokermann G, Cholewa D, Bork S, Walenda T, Koch C et al (2010) Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells. Cytotherapy 12(7):888–898
41. Lohmann M, Walenda G, Hemeda H, Joussen S, Drescher W, Jockenhoevel S et al (2012) Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells. PloS One 7(5):e37839
42. Hemeda H, Kalz J, Walenda G, Lohmann M, Wagner W (2013) Heparin concentration is critical for cell culture with human platelet lysate. Cytotherapy 15(9):1174–1181
43. Secco M, Zucconi E, Vieira NM, Fogaca LL, Cerqueira A, Carvalho MD et al (2008) Multipotent stem cells from umbilical cord: cord is richer than blood! Stem Cells 26(1):146–150
44. Ben Azouna N, Jenhani F, Regaya Z, Bereaies L, Ben Othman T, Ducrocq E et al (2012) Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res Ther 3(1):6